Protagonist Therapeutics (PTGX) Competitors $41.11 +0.07 (+0.17%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PTGX vs. AMPH, FPRX, CALT, PAHC, ESPR, RVMD, QGEN, ITCI, ROIV, and ASNDShould you be buying Protagonist Therapeutics stock or one of its competitors? The main competitors of Protagonist Therapeutics include Amphastar Pharmaceuticals (AMPH), Five Prime Therapeutics (FPRX), Calliditas Therapeutics AB (publ) (CALT), Phibro Animal Health (PAHC), Esperion Therapeutics (ESPR), Revolution Medicines (RVMD), Qiagen (QGEN), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), and Ascendis Pharma A/S (ASND). These companies are all part of the "medical" sector. Protagonist Therapeutics vs. Amphastar Pharmaceuticals Five Prime Therapeutics Calliditas Therapeutics AB (publ) Phibro Animal Health Esperion Therapeutics Revolution Medicines Qiagen Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Amphastar Pharmaceuticals (NASDAQ:AMPH) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings. Do insiders & institutionals believe in AMPH or PTGX? 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 5.4% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend AMPH or PTGX? Amphastar Pharmaceuticals presently has a consensus price target of $63.00, indicating a potential upside of 41.22%. Protagonist Therapeutics has a consensus price target of $53.57, indicating a potential upside of 30.31%. Given Amphastar Pharmaceuticals' higher probable upside, analysts plainly believe Amphastar Pharmaceuticals is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amphastar Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Protagonist Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Does the media refer more to AMPH or PTGX? In the previous week, Protagonist Therapeutics had 12 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 17 mentions for Protagonist Therapeutics and 5 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 0.63 beat Protagonist Therapeutics' score of 0.59 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, AMPH or PTGX? Amphastar Pharmaceuticals has higher revenue and earnings than Protagonist Therapeutics. Amphastar Pharmaceuticals is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmphastar Pharmaceuticals$644.40M3.33$137.54M$3.0014.87Protagonist Therapeutics$60M40.84-$78.96M$2.6615.45 Which has more volatility and risk, AMPH or PTGX? Amphastar Pharmaceuticals has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500. Is AMPH or PTGX more profitable? Protagonist Therapeutics has a net margin of 52.76% compared to Amphastar Pharmaceuticals' net margin of 21.80%. Protagonist Therapeutics' return on equity of 34.68% beat Amphastar Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amphastar Pharmaceuticals21.80% 26.44% 11.89% Protagonist Therapeutics 52.76%34.68%30.98% Does the MarketBeat Community believe in AMPH or PTGX? Amphastar Pharmaceuticals received 118 more outperform votes than Protagonist Therapeutics when rated by MarketBeat users. Likewise, 66.33% of users gave Amphastar Pharmaceuticals an outperform vote while only 60.89% of users gave Protagonist Therapeutics an outperform vote. CompanyUnderperformOutperformAmphastar PharmaceuticalsOutperform Votes39266.33% Underperform Votes19933.67% Protagonist TherapeuticsOutperform Votes27460.89% Underperform Votes17639.11% SummaryProtagonist Therapeutics beats Amphastar Pharmaceuticals on 11 of the 19 factors compared between the two stocks. Ad ReticulateThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTGX vs. The Competition Export to ExcelMetricProtagonist TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.45B$6.39B$5.06B$8.66BDividend YieldN/A8.04%5.09%4.06%P/E Ratio15.4510.80101.8517.37Price / Sales40.84245.131,196.8169.07Price / CashN/A53.4940.9136.36Price / Book4.609.306.335.87Net Income-$78.96M$154.14M$119.64M$225.66M7 Day Performance-11.08%-9.49%-5.12%-1.34%1 Month Performance-12.51%-7.23%-3.21%1.00%1 Year Performance155.02%30.70%32.52%25.27% Protagonist Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTGXProtagonist Therapeutics3.0657 of 5 stars$41.11+0.2%$53.57+30.3%+155.0%$2.45B$60M15.45125Analyst RevisionHigh Trading VolumeAMPHAmphastar Pharmaceuticals4.88 of 5 stars$45.48-4.7%N/A-20.6%$2.19B$644.40M15.161,761Insider SellingFPRXFive Prime TherapeuticsN/A$38.00flatN/AN/A$1.77B$14.87M-14.1887CALTCalliditas Therapeutics AB (publ)0.1943 of 5 stars$40.00flatN/AN/A$1.19B$1.60B-21.62180News CoveragePAHCPhibro Animal Health4.3687 of 5 stars$25.27+0.8%N/A+132.3%$1.02B$1.02B58.771,940Analyst UpgradeESPREsperion Therapeutics4.1089 of 5 stars$2.23-8.2%N/A+91.0%$439.40M$116.33M-3.48240Analyst DowngradeRVMDRevolution Medicines3.5596 of 5 stars$58.13-2.0%N/A+159.4%$9.78B$11.58M-16.19443QGENQiagen4.2892 of 5 stars$42.63-1.4%N/A+1.6%$9.73B$1.97B109.315,967Analyst RevisionITCIIntra-Cellular Therapies4.5093 of 5 stars$88.22-0.3%N/A+51.6%$9.35B$464.37M-101.40560Insider SellingPositive NewsROIVRoivant Sciences3.4226 of 5 stars$11.95+2.7%N/A+24.2%$8.84B$124.79M2.12860Analyst ForecastNews CoverageASNDAscendis Pharma A/S3.06 of 5 stars$126.03-1.3%N/A+35.3%$7.64B$288.08M-13.54640Analyst DowngradeShort Interest ↑News CoverageGap Down Related Companies and Tools Related Companies Amphastar Pharmaceuticals Alternatives Five Prime Therapeutics Alternatives Calliditas Therapeutics AB (publ) Alternatives Phibro Animal Health Alternatives Esperion Therapeutics Alternatives Revolution Medicines Alternatives Qiagen Alternatives Intra-Cellular Therapies Alternatives Roivant Sciences Alternatives Ascendis Pharma A/S Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PTGX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTGX Stock Alerts